Retatrutide does not have a price yet. It is investigational, no regulator has approved it, and its developer, Eli Lilly, says it cannot be sold to consumers. So there is no retail monthly price and no insurance coverage to check today. What you can compare right now is what approved GLP-1 weight-loss medicines cost.
Why retatrutide has no price yet
In August 2026, Lilly said no medicine containing retatrutide has been approved for human use by any regulator in the world, and that it cannot be sold to consumers. Lilly’s retatrutide page, updated September 2026, says the drug is legally available only through its clinical trials. STAT reported that in August 2026 Lilly would also open special access to a limited number of patients who meet specific medical criteria and cannot join a trial. That route runs through a doctor. It is not a store purchase.
Lilly has described its pricing intent only in general terms. It plans to price the drug to reflect its overall value to the health system, once trials and regulatory review are complete. Lilly plans to file with the FDA in the first quarter of 2027. The FDA’s PDUFA performance goals for fiscal years 2023 through 2027 aim for a decision about 12 months after filing on a standard review, or about 8 months on a priority review. Those are targets, not guarantees, and the FDA can ask for more data. On those timelines, a price would not appear before the second half of 2027.
The trial results are real, but they are not a price. In a phase 2 trial of 338 adults with obesity or overweight, people taking the 8 mg or 12 mg dose lost roughly 23% to 24% of their body weight after one year. The placebo group lost less than 2%. WebMD’s obesity drug pipeline article summarizes this and other trials. None of those results says what the medicine will cost.
What approved GLP-1 weight-loss medicines cost now
These are the closest real figures you can use. They are the manufacturers’ own self-pay prices. Prices change, so check the manufacturer’s pricing page for today’s number before you decide. For how tirzepatide and semaglutide compare in clinical research, read our tirzepatide vs semaglutide for weight loss guide.
| Medicine | Form | Self-pay price per month | Source and date |
|---|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg) | LillyDirect, checked October 19, 2026 |
| Semaglutide (Wegovy) | Weekly injection pen | $199 for the first two months for new patients at 0.25 mg and 0.5 mg; $349 (0.25 mg to 2.4 mg); $399 (7.2 mg) | NovoCare, checked October 19, 2026 |
| Semaglutide (Wegovy) | Daily tablet | $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) | NovoCare, checked October 19, 2026 |
| Orforglipron (Foundayo) | Daily tablet | $149 (0.8 mg and 2.5 mg), $199 (5.5 mg), $299 (9 mg to 17.2 mg) | LillyDirect, checked October 19, 2026 |
| Retatrutide | Weekly injection (investigational) | No price: not approved | Lilly, August 2026 |
Several of these prices come with conditions. Lilly’s prices for tirzepatide at 7.5 mg and above, and for orforglipron at 14.5 mg and 17.2 mg, apply when a refill is made within 45 days. Lilly has temporarily reduced its orforglipron 2.5 mg and 5.5 mg prices through December 31, 2026. Novo Nordisk’s $199 semaglutide price is for new patients only, covers two monthly fills, and runs through December 31, 2026. The company says it will update pricing after that date.
Semaglutide’s injection also carries a list price of $1,349.02 per package. In a February 24, 2026 announcement, Novo Nordisk said the list price will fall to $675 a month from January 1, 2027. List prices are the starting point for insurance, so most people do not pay them directly.
Will insurance cover retatrutide?
No one can say yet. Coverage decisions depend on a medicine’s label and price, and retatrutide has neither. The coverage questions you can answer today concern the approved medicines a prescriber might recommend instead.
| Option | What you pay | Who it applies to | Source |
|---|---|---|---|
| Manufacturer savings offers | As low as $25 a month | People whose commercial insurance covers the drug and who qualify. Novo Nordisk caps its savings at $100 a month. People with government insurance such as Medicare are excluded. | Lilly and Novo Nordisk pricing pages, checked October 19, 2026 |
| Medicare GLP-1 Bridge | $50 a month | Eligible people with Medicare Part D drug coverage, based on BMI and certain health conditions. Covers three named drugs from July 1, 2026 to December 31, 2027. | Centers for Medicare & Medicaid Services |
| Retatrutide | No price and no coverage decision | Not approved, so there is nothing to cover | Lilly, August 2026 |
The Medicare GLP-1 Bridge names three drugs: orforglipron tablets, semaglutide injections or tablets, and tirzepatide multi-dose pens. Retatrutide is not on that list. Weight-management coverage varies from plan to plan, so ask your insurer what it covers for the medicine your prescriber recommends. This is general information about these programs, not legal or insurance advice.
Why online retatrutide prices are not real prices
You will see monthly figures of about $1,000 to $1,500 online. Those are websites’ own projections. They are not attributed to Lilly or to any named analyst. Products sold online under the retatrutide name are not sold or supplied by Lilly. Lilly’s retatrutide page warns that illicit products may contain unknown ingredients, harmful contaminants and impurities. In August 2026, Lilly asked online platforms, payment companies and regulators to shut down the illegal retatrutide market. For a broader look at weight-loss products sold online, see our weight loss supplements reader guide.
For compounded GLP-1 products in general, the National Academy of Medicine’s GLP-1 basics notes that the FDA has not assessed compounded versions for safety, effectiveness or quality, and that some may be fraudulent and missing their active ingredient. Harvard Health’s GLP-1 explainer adds that the FDA has issued warnings about compounded GLP-1 drugs after reports of harmful side effects.
Other questions people ask with this search
WebMD describes retatrutide as a once-weekly shot under the skin, not a pill. Cagrilintide is a separate medicine. It works like the hormone amylin, and it is one part of CagriSema, which pairs it with semaglutide. Retatrutide targets three hormone receptors: GIP, GLP-1 and glucagon. Starting amounts and dosing charts depend on an approved label and your prescriber’s instructions. Retatrutide has neither yet, so a dosing chart you find online is not a reliable guide.
What to check before you pay anything
What is not known yet is the price, whether insurers will cover retatrutide, and when, or whether, it will be approved.
- Check the current self-pay price for any approved GLP-1 on the manufacturer’s own pricing page.
- Ask your prescriber which approved option fits your situation, and ask your insurer what your plan covers for it.
- Watch Lilly’s retatrutide page for any price or approval announcement.
- Treat any retatrutide listing from a website as unapproved, because Lilly says the medicine cannot be sold to consumers.
Disclosure: this page contains no purchase or affiliate links.
By the Clinical Research Explained Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.